

NPC Detect Sponsored Testing Program

Zevra Therapeutics, in partnership with GeneDx, is offering a no-cost genetic testing program for individuals with suspected Niemann-Pick disease type C (NPC), an ultra-rare, progressive genetic disorder that affects the body's ability to transport cholesterol and other lipids within cells.



Is your patient eligible? Patients must meet all of the following criteria:

- ✓ Suspected of having Niemann-Pick disease type C (NPC)
- ✓ Must present with all three (3) of the following symptoms:
 1. Ataxia
 2. Dysphagia
 3. Either developmental delay, developmental regression, or intellectual disability
- ✓ Reside in the USA
- ✓ No prior genetic testing performed by clinical laboratory which explained patient's symptoms
- ✓ The ordering provider must be authorized under applicable laws to order genetic testing in the US
- ✓ Must consent to sharing de-identified data with Zevra Therapeutics

From sample received to report in as soon as 2 weeks

- Order is placed by healthcare provider
- Kit is shipped to patient
- Sample is collected and kit is shipped to GeneDx
- Sample is processed and results are analyzed
- Results are delivered to healthcare professional

Your patient's data stays private

GeneDx will not share any personally identifiable patient information or raw sequencing data with Zevra Therapeutics or with other biopharma industry partners.

How to order

- 1 Login or sign up for a GeneDx account and add **ExomeDx™, proband** to your cart
- 2 Select the program code STP-NPC
- 3 Confirm your patient's eligibility
- 4 Follow the prompts and enter in the appropriate information
- 5 Place your order and GeneDx will follow up when your results are ready



Ordering also available
via paper program TRF

For access to the program-specific TRF, please scan the QR code or visit [genedx.com/providers/genetic-testing-programs/npc-detect](https://www.genedx.com/providers/genetic-testing-programs/npc-detect)

Find answers with exome sequencing

Exome sequencing targets the protein-coding regions (exons) of approximately 20,000 genes, which account for about 2% of the human genome but contain the majority of known disease-causing variants.¹ This targeted approach provides a high-yield, efficient path to diagnosis, particularly for patients with complex, heterogeneous, or unexplained conditions. Using a proprietary capture system with next-generation sequencing and CNV calling, GeneDx analyzes sequence variants and most deletions and duplications involving three or more coding exons. Across the exome, average depth of coverage is 100–120x, with 98% of coding regions assessed at $\geq 10\times$ coverage. All testing is performed in GeneDx's CLIA-certified and CAP-accredited laboratory.



Remove barriers to testing.
Empower earlier insights.